MYXREDLIN (Insulin Human) in 0.9% Sodium Chloride Injection
100 units per 100 mL (1 unit/mL)

Indication

MYXREDLIN is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

IMPORTANT RISK INFORMATION

Contraindications

• During episodes of hypoglycemia
• Hypersensitivity to insulin human or any of the excipients in MYXREDLIN

Warnings and Precautions

• Hyper- or Hypoglycemia with Changes in Insulin Regimen: Carry out under close medical supervision and increase frequency of blood glucose monitoring.
• Administer MYXREDLIN intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels. Hypokalemia may be life-threatening if not treated.
• Individualize dose based on metabolic needs, blood glucose monitoring results, and glycemic control goal. Dosage adjustments may be needed with changes in nutrition, renal, or hepatic function or during acute illness.
• Adverse reactions observed with insulin human injection include hypoglycemia, allergic reactions, weight gain and edema.
• Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; such as shortness of breath, swelling of your ankles or feet, or sudden weight gain.

Dosage and Administration

• Inspect MYXREDLIN visually before use. It should appear clear and colorless. Do not use MYXREDLIN if particulate matter or coloration is seen.
• Do not add supplementary medication or additives.
• Do not use in series connections.
• Do not shake or freeze. Discard unused portion.